Caption Management’s Protagonist Therapeutics PTGX Stock Holding History

Caption Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19.8M	Buy	161,800 +150,000	+1,271%	+$15.7M	0.09%	230
2026 Q1	$1.24M	Buy	+11,800	New	+$1.04M	0.01%	949
2025 Q3	–	Sell	-143,000	Closed	-$7.9M	–	1970
2025 Q2	$7.9M	Sell	143,000 -50,900	-26%	-$2.44M	0.09%	272
2025 Q1	$9.38M	Buy	193,900 +104,700	+117%	+$4.39M	0.09%	221
2024 Q4	$3.44M	Hold	89,200	–	–	0.03%	503
2024 Q3	$4.01M	Buy	+89,200	New	+$3.6M	0.06%	355
2022 Q3	–	Sell	-80,000	Closed	-$633K	–	1782
2022 Q2	$633K	Buy	+80,000	New	+$967K	0.01%	1018
2022 Q1	–	Sell	-233,600	Closed	-$7.99M	–	1844
2021 Q4	$7.99M	Sell	233,600 -3,900	-2%	-$123K	0.09%	315
2021 Q3	$4.21M	Buy	+237,500	New	+$10.1M	0.05%	524

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Caption Management's PTGX Position: Q2 2026 in Review

Caption Management opened a new position in Protagonist Therapeutics (PTGX) in Q2 2026: 45,000 shares worth $5.52M. The stake represents 0.03% of the portfolio and ranks #554 among its holdings. This is a return to the name: Caption Management previously reported a position in PTGX as recently as Q4 2024.

Caption Management first reported a position in PTGX in Q3 2021 and has held it in 11 quarters since. The position peaked at $6.59M in Q4 2021. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Caption Management held 45,000 shares of Protagonist Therapeutics worth $5.52M as of Q2 2026.
Protagonist Therapeutics was a new Caption Management position in Q2 2026.
Protagonist Therapeutics made up 0.03% of Caption Management's portfolio in Q2 2026, its #554 holding.
Caption Management first reported a position in Protagonist Therapeutics in Q3 2021 and has held it in 11 quarters since.
Caption Management's Protagonist Therapeutics position peaked at $6.59M in Q4 2021.
343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.